Evaluation of the effect of micropulse laser photocoagulation combined with ranibizumab in the treatment of secondary ME caused by retinal branch vein occlusion

WANG Xue; JIANG Hai-tao; REN Zeng-jin

doi:10.3969/j.issn.1672-8157.2023.06.010

Abstract：Objective:To assess the effectiveness of rabizumab combined with macular micropulse laser for the therapy of mac-ular edema(ME)resulting from branch retinal vein occlusion(BRVO)Methods:Retrospective data analysis was used in this study,from February 2020 to December 2022,90 patients with ME secondary to BRVO in Lianyungang First People's Hospital hospital(all of them suffered from monocular disease)were selected and divided into the two group according to the different treatment methods.The control group(45 cases)received intravitreal injection of ranibizumab,while the study group(45 cases)received ranibizumab combined with mac-ular micropulse laser photocoagulation.45 patients in the control group were treated with intravitreal injection of ranibizumab,while ranibi-zumab in conjunction with retinal laser photocoagulation was administered to 45 participants in the study group.The clinical effects of the two groups were compared at 1,3and 6 months after treatment.Results:The BCVA and CMT of the two groups at 1,3,and 6 months after treatment were lower than those before treatment.The BCVA and CMT of the control group at 3 and 6 months after treatment were lower than those at 1 month after treatment,while the BCVA and CMT of the study group at 3 and 6 months after treatment were lower than those at 1 month after treatment.While there were differences among different time points in study group at 1,3,and 6 months after treatment(P<0.05).In addition,BCVA(0.29±0.05)and CMT(205.37±13.84)in the study group were lower than those in the control group 6 months after treatment(0.40±0.06,236.58±15.07),and the difference was statistically significant(P<0.05).The number of ranibizumab injections in the study group(3.51±0.88)within 6 months of treatment was less than that in the control group(4.25±1.02),the difference was sta-tistically significant(P<0.05),while the recurrence rate of 2 groups was not statistically obvious(P>0.05).There was no difference in the incidence of complications between 2 groups after treatment(P>0.05).Conclusion:The clinical effect of macular micropulse laser photo-coagulation combined with ranibizumab in the treatment of patients with me secondary to BRVO is better,and is worthy of clinical application.